In order to evaluate the influence of Th1-related cytokines on disease were examined in 337 Japanese patients with histologically confirmed primary adenocarcinomas of the stomach and colorectal and in 172 control subjects.
Introduction
It is still difficult to discover early-stage cancers, though preventive medicine has become more important. (Brunda, Luistro et al., 1993; Cassatella, Meda et al., 1995; Chan, Kobayashi et al., 1995) . Both cytokines seem to modulate and optimize the immune responses, including anti-tumor responses, originally initiated in an antigenspecific or non-specific manner .
In order to evaluate the influence of Th1-related cytokines on disease cells were examined in patients with primary adenocarcinomas of the stomach and the colorectal and in normal healthy subjects.
Patients and Methods
Three-hundred and thirty-seven Japanese patients diagnosed between November The analyses were performed with a commercially available statistical package (SPSS Ver 10.0). We used Mann-Whitney U and Kruskal-Wallis tests for the comparison.
A result was considered significant when the p value was less than 0.05.
ANNALS OF Cancer Research and Therapy
Results significantly higher than those in cancer patients, while levels of Th2 and NK cell activity in normal healthy controls were lower than those in cancer patients (Table III) . significantly higher than those in patients with early-stage gastric cancer, while NK cell activity in normal healthy controls was significantly lower than that in cancer patients.
also significantly higher and lower, respectively, than those in patients with early-stage colon and rectal cancer. In the advanced-stage gastric and colorectal cancers, similar results were obtained. Levels of NK cell activity in patients with colon cancers differed significantly between those with early-stage and those with late-stage cancers. Between gastric and colorectal cancers there was no significant difference even when early-stage and advanced patients were compared (Table IV) .
Discussion of Th1 cells (Cassatell, Meda, et al., 1995) . These Th1-related cytokines are shown to negatively modulate the growth of tumors. In animal models, Th1 cells have been shown to be activated shortly after the implantation of tumor cells and to exert anti-tumor effects, but these activities were suppressed and overwhelmed by expanding Th2 cells as tumor cells grew (Zou, Shimizu et al., 1992) .
Our results demonstrated that levels of mitogen-induced Th1-related cytokines patients than those in the normal healthy control group, while that of the Th2 subset and NK cell activity was higher in cancer patients compared to those in the control group.
Among early-and advanced-stage cancer patients, there was no difference between these levels, except levels of NK cell activity in those with colon cancer.
Due to previous studies of Th1 and Th2 subsets (Gately, Desai et al., 1991; Mosmann, Cherwinski et al., 1986) , the mechanism of the positive interaction between Trinchieri, 1993; and Tripp, Kanagawa et al., 1995) . APCs produce IL-12, which stimulates Th1 cells (Gately, Wolitzky et al., 1992; Locksley, 1993; and Romagnani 1994) to proliferate and differentiate into effector cells, including cytotoxic T cells (Gately, Desai et al., 1991) , and delayed-type hypersensitivity-committed T cells show anti-tumor responses in the presence of Th1-related cytokines. Later in the process of tumor progression, the Th1 system was down-regulated and overwhelmed by the Th2 system, which allowed tumor cells to grow (Corry, Reiner et al., 1994; Kishikawa, Song Luistro et al., 1993; Mu, Zou et al., 1995; and Zou, Shimizu et al., 1992 ) also seem to participate in T cell-mediated anti-tumor immunity. In this study we demonstrated that levels of Th1-related cytokines were lower in cancer patients than those in the control group, even in the early-stage patients, which appeared compatible with the abovementioned findings in mice. These cytokines were already down-regulated at an early stage, there being no difference between early-stage and advanced-stage patients.
IL-12 was originally found to be a cytokine that stimulates NK cells (Kobayashi, Fitz et al., 1989; Liebermann, Siegal et al., 1991; and Yago, Tukuda et al., 1998) , and NK cells were found to be required for IL-12 induced anti-tumor responses in mice (Pham-Nguyen, Yang et al., 1999) . In the present study, NK cell function was not impaired in cancers. The result of these studies and our data suggest that even in earlystage cancer, the Th1 system is already impaired. However, this is quite different from the results of animal model reports, in which the Th1 system was activated shortly after the implantation of tumors (Siders, Wright et al., 1998) .
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In this study, we employed in vitro mitogenic stimulation to evaluate cytokine production and Th subset induction. In this investigation we were clearly determining the function not only of tumor-specific T cell clone(s) but also of other T cells. Therefore, the fact that we detected abnormal Th1 functions in patients with cancer suggests that detected abnormalities were not limited to the tumor-specific Th1 subset and its precursor, but also spread to other T cell repertoires that would be involved in other specific cancers.
The Th1-related immune system may have been impaired in patients whose tumor cells were small in size and this may have affected the immune system, being down-regulated by a Th1-related function. Therefore, we conclude that Th1-related immune parameters might be useful immunological markers for detecting groups at high risk for cancer among subjects undergoing medical examinations.
